Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x. x č. 46/2008 Xx. m. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 98/2013 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 11. xxxxxxxxx 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Seznamu xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament České xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal listinu x xxxxxxx xxxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx znění Přílohy X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2014 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx I x xxxxxxxx přestalo platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx pod č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x její překlad xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.

¹⁾ Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 v Xxxxxx byla vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX SPORTU
Příloha X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX XXXXXXXXXX LÁTEK X METOD DOPINGU XXX ROK 2014

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2014

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx metod X1, X2 x M3.

LÁTKY X METODY XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

XXXXXXXX LÁTKY

S0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x následujících xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), je xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; klostebol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; methandriol; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; stenbolon; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-hyroxyestr-4,9,11-trien-3-on) x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx exogenně:

Androstendiol (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (androst-4-en-3,17-dion), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx pouze xx ně:

5α-androstan-3α,17α-diol	5-androstendion (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx sekce:

* "exogenní" xx vztahuje x xxxxx, kterou xxxx xxxxxxxx přirozeně xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx x mužů;

3. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx;

4. Růstový xxxxxx (XX) x xxxx xxxxxxxxxx faktory x xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1).

Kromě xxxx jsou xxxxxxxx xxxxxxxxxxx růstové faktory:

Fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), mechanické xxxxxxx xxxxxxx (MGF), xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx destiček (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), xxxxxx xxxx jakékoliv xxxx xxxxxxx faktory xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x vaziva, krevní xxxxxxxx, využití energie, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S3. XXXX2- XXXXXXXX

Xxxxxxx beta-2 xxxxxxxx, xxxxxx xxxxx případných xxxxxxxxx isomerů (např. x- x l-), xxxx zakázáni xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx), xxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx, pokud xxxx xxxxxx v xxxxxxxx v xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší než 1000 xx/xx x xxxxxxxxxx formoterolu x xxxx v xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx za pozitivní xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx výsledek xxx xxxxxxxx užíváním xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx uvedené xxxxxxx.

X4. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, ale ne x xxxxxxxx pouze xx xx.

2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

5. Metabolické xxxxxxxxxx:

x) Xxxxxxxx;

x) Xxxxxxxx xxxxx aktivovaný peroxizomovými xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové osy xxxxxxxxxx XXX v xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Maskovací látky xxxx xxxxxxxx. Zahrnují:

Diuretika, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), probenecid x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. xxxxxxxxx) x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx na diuretikum xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. MANIPULACE X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (homologní) xxxx xxxxxxxxxxx krve xxxx červených xxxxxxx x xxx podobných xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie x xxxxxxxxxxx (XXX13), ale xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Dopingové xxxxxxxx. Xx zahrnuje xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx na xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx modifikovaných buněk.

LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až X5 x M1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (např. d- x l-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx jejich místního xxxxxxx a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, etylefrin, famprofazon, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, katin**, xxxxxxx x jeho xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), níketamid, xxxxxxxxxxx, oktopamin, oxilofrin (xxxxxxxxxxxxx), pemolin, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, selegilin, xxxxxxxxxx, strychnin, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x další látky x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, fenylefrin, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou považovány xx Xxxxxxxx xxxxx.

** Xxxxx xx xxxxxxxx xxxxx xxx koncentraci xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxx xxxxxx xxxxxxxxxx (epinefrinu) (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky není xxxxxxxx.

***** Pseudoefedrin xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x kanabimimetika (xxxx. "Xxxxx", XXX018, JWH073 x HU-210) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

LÁTKY XXXXXXXX X XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxxxxxx alkoholu x xxxx 0.10 x/x.

• Automobilový xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx sport (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. BETA-BLOKÁTORY

Pokud není xxxxx xxxxxx, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Xxxx (IGF)

• Xxxxxxxxxxx (XX) (zakázané xxxx Xxxx xxxxxx)

• Lyžování (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, bisoprolol, bunolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, levobunolol, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, propranolol, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 47/2014 Xx. x. x. xxxxx účinnosti xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx v xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx jich xxxxxx derogační změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.